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Abstract
Background: This study evaluated the efficacy and safety of the long-acting b2-agonist formoterol in patients with
moderate-to-severe COPD.
Methods: This double-blind, placebo-controlled, parallel-group, multinational phase III study randomized patients ≥
40 years of age with moderate-to-severe COPD to inhaled formoterol 4.5 or 9 μg twice daily (bid) via Turbuhaler
®
or placebo for 12 weeks. Salbutamol 100 μg/actuation via pMDI was permitted as reliever medication. The primary
outcome variable was change (ratio) from baseline to treatment period in FEV1 60-min post-dose.
Results: 613 patients received treatment (formoterol 4.5 μg n = 206; 9 μg n = 199; placebo n = 208); 539 (87.9%)
male; 324 (52.9%) Japanese and 289 (47.1%) European. End of study increases in FEV1 60-min post-dose were
significantly greater (p < 0.001 for both) with formoterol 4.5 and 9 μg bid (113% of baseline for both) than with
placebo, as were all secondary outcome measures. The proportion of patients with an improvement in St George’s
Respiratory Questionnaire score of ≥ 4 was 50.2% for formoterol 4.5 μg (p = 0.0682 vs. placebo), 59.2% (p = 0.0004)
for 9 μg, and 41.3% for placebo. Reduction in reliever medication use was significantly greater with formoterol vs.
placebo (9 μg: -0.548, p < 0.001; 4.5 μg: -0.274, p = 0.027), with 9 μg being significantly superior to 4.5 μg (-0.274,
p = 0.029). Formoterol was well tolerated with the incidence and type of adverse events not being different for
the three groups.
Conclusions: Formoterol 4.5 μg and 9 μg bid was effective and well tolerated in patients with COPD; there was
no difference between formoterol doses for the primary endpoint; however, an added value of formoterol 9 μg
over 4.5 μg bid was observed for some secondary endpoints.
Trial registration: NCT00628862 (ClinicalTrials.gov); D5122C00001 (AstraZeneca Study code).
Background
Chronic obstructive pulmonary disease (COPD) is a
chronic, progressive respiratory disease that follows a
course of declining lung function and markedly
impaired quality of life, and places patients at a signifi-
cantly increased risk of premature death [1,2]. The pul-
monary component of the disease is characterized by
airflow obstruction that is not fully reversible and is
associated with symptoms of breathlessness, cough, and
reduced physical exercise capacity resulting from
inflammatory and destructive changes in the lungs.
Exacerbations are common, particularly in severe stages
of the disease, and frequently lead to hospitalization and
can be life-threatening.
Bronchodilator therapy is the mainstay of pharma-
cotherapy for COPD with treatment with short-acting
bronchodilators being recommended in patients with
mild COPD, while long-acting b2-agonists (LABAs) and
anticholinergics are added for patients with moderate to
severe COPD. Despite an underlying inflammatory
component to the disease, the use of LABAs for the
treatment of COPD is generally advocated without con-
comitant inhaled corticosteroid (ICS) therapy. ICS
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in some studies [3,4], while improvements in symptom
control, lung function and all-cause mortality has been
reported with the combination of ICS/LABA budeso-
nide/formoterol [5-7] and fluticasone propionate/salme-
terol [8]. Consequently, COPD guidelines (Global
Initiative for Chronic Obstructive Lung Disease
[GOLD]) include bronchodilator therapy as the primary
treatment in COPD without mandating concomitant use
of anti-inflammatory therapy [9].
Some concerns have existed in the past regarding the
safety of LABAs in patients with airway disease, fueled
by a meta-analysis conducted by Salpeter et al [10] that
suggested there was a doubling of the risk of respiratory
death in COPD with the use of a LABA compared with
placebo. In a more recent meta-analysis, Rodrigo and
coworkers [11] came to a different conclusion to those
of Salpeter and colleagues [10], reporting no increased
risk of mortality in COPD patients using LABAs. The
difference in these findings may partly relate to differ-
ences in trial selection [10,11].
The objective of this study was to evaluate the efficacy
and safety of two doses of the LABA formoterol, 4.5
and 9 μg twice daily (bid), in Japanese and European
patients with COPD.
Methods
Design
This was a randomized, double-blind, placebo-
controlled, parallel-group, multinational (Japan,
Romania, Russia and Ukraine) phase III study (Study
code: D5122C00001; ClinicalTrials.gov identifier:
NCT00628862) conducted at 65 centers in Japan and
Europe. The study protocol was approved by the
Institutional Review Board/Ethics Committee at all
participating sites and the study was performed in
accordance with the Declaration of Helsinki and the
AstraZeneca policy on Bioethics and Human Biological
Samples. All patients provided written informed con-
sent prior to enrolment into the study.
The primary objective was to show that formoterol 4.5
and 9 μg bid for 12 weeks were superior to placebo in
Japanese and European patients with COPD using
forced expiratory volume in 1 second (FEV1) 60-min
post-dose as the primary outcome variable.
The study consisted of an enrolment period for with-
drawal of pre-study medication, a 2-week run-in period
and a 12-week treatment period. Clinic visits took place
at baseline (on completion of the 2-week run-in period),
and at weeks 4, 8, and 12 of the treatment period.
Study population
Male and female patients ≥ 40 years of age with a clini-
cal diagnosis of COPD (post-bronchodilator FEV1 < 80%
of predicted normal, and post-bronchodilator FEV1/
forced vital capacity [FVC] < 70%) and current COPD
symptoms were eligible for inclusion. Patients were also
required to have a current or previous smoking history
of ≥ 10 pack-years and a symptom score of at least 2
points (combination of breathlessness, cough, and/or
night time awakenings due to symptoms; each assessed
b yt h ep a t i e n t so nas c a l eo f0 - 4w h e r e0=n os y m p -
toms and 4 = severe symptoms) on at least 6 of the last
10 days of the run-in period.
Patients with a history and/or current clinical diagno-
sis of asthma were excluded from participating, as were
those with a history and/or current clinical diagnosis of
atopic disease such as allergic rhinitis. Additional exclu-
sion criteria included use of an ICS within 4 weeks of
the run-in period, COPD exacerbation requiring hospi-
talization and/or a course of antibiotics and/or systemic
steroid therapy within 4 weeks of the run-in period, sig-
nificant or unstable ischemic heart disease, or other
relevant cardiovascular conditions, any other respiratory
tract disorders or significant disease likely to place the
patient at risk during the study.
Study treatments
Patients received inhaled formoterol 4.5 or 9 μgt w i c e
daily (bid) via Turbuhaler
® or matching placebo for 12
weeks. Study treatments were taken at approximately
the same time every morning and evening and immedi-
ately after measuring peak expiratory flow (PEF).
Salbutamol 100 μg / a c t u a t i o nv i aap r e s s u r i z e d
metered-dose inhaler (pMDI) was available to relieve
symptoms throughout the study period and patients
could continue to take short-acting anticholinergics.
Patients previously receiving long-acting anticholinergics
were switched to short-acting anticholinergics at the
start of the enrolment period. Glucocorticosteroid treat-
ment was not permitted at any time during the study.
Outcomes
The primary outcome variable was change (ratio) from
baseline to the end of treatment period in FEV1 60-min
post-dose. Secondary outcome variables included spiro-
metry, diary variables, and assessment of health-related
quality-of-life (HRQL). Spirometry endpoints were FVC
60-min post-dose, FEV1 and FVC pre-dose and 5-min
post-dose. Diary variables were morning and evening
PEF, COPD symptom scores (night-time awakenings
due to symptoms, breathlessness, and cough), and use
of salbutamol as reliever medication (measured as inha-
lations/day). HRQL was assessed using the St George’s
Respiratory Questionnaire (SGRQ).
Safety and tolerability were assessed by evaluation of
the nature, incidence and severity of adverse events,
clinical laboratory variables including clinical chemistry,
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(ECG), blood pressure and pulse rate.
Statistical analyses
Sample size selection was based on clinical data derived
from a published 6-month study [12]. With a two-sided
test at level 0.05 and 176 patients per treatment group,
the study was determined to have 80% power to detect
a difference between the treatment groups of at least
0.06 L in the change from baseline FEV1 value.
A last-observation-carried-forward (LOCF) approach
was used to account for any missing week 6 data. The
comparison of formoterol 4.5 and 9 μg bid with pla-
cebo was performed on the primary endpoint, mean
change from baseline in FEV1 60-min post-dose, using
an analysis of covariance (ANCOVA) model including
country and treatment as fixed factors and the baseline
value as covariate. A two-sided 5% significance level
was used and 95% confidence intervals (CIs) for the
mean difference between each dose of formoterol and
placebo were calculated. The multiplicity of statistical
tests was adjusted by a “closed testing procedure”
under which the null hypothesis that 9 μgb i dw a s
equal to placebo was tested; if this null hypothesis was
rejected then the 4.5 μg bid dose versus placebo was
tested.
As for FEV1, the comparison of active treatments (for-
moterol 4.5 μga n d9μg bid) with placebo for the sec-
ondary variables was performed using an ANCOVA
model including country and treatment as fixed factors
and the baseline value as covariate. The ANCOVA
model used in the analysis was multiplicative. A two-
sided 5% significance level was used and the “closed
testing procedure” was applied.
The incidence of adverse events was calculated, and
results from laboratory safety measurements, vital signs,
and ECG, were analyzed primarily by means of descrip-
tive statistics.
Results
A total of 613 patients were randomized to treatment
(formoterol 4.5 μg bid n = 206; 9 μg bid n = 199; pla-
cebo n = 208); 539 (87.9%) patients were male; 324
(52.9%) patients were Japanese and 289 (47.1%) were
European. The mean duration of COPD since diagnosis
was 4.5 years (range 0-39 years), the mean post-bronch-
odilator FEV1 w a s5 1 %o fp r e d i c t e dn o r m a l ,a n dt h e
FEV1/FVC was 46%. Of the 613 randomized patients,
563 patients completed the study (formoterol 4.5 μgb i d
n = 195; 9 μg bid n = 182; placebo n = 186) and 50
patients discontinued treatment (formoterol 4.5 μg bid n
=1 1 ;9μg bid n = 17; placebo n = 22); the flow of
patients through the study and reasons for discontinua-
tion are shown in Figure 1. There were no major
differences in baseline characteristics between the three
treatment groups (Table 1).
Disease-related treatment prior to enrolment included
anticholinergics (55.5% of patients), inhaled selective b2-
agonists (49.1%), xanthines (18.6%), mucolytics (16.0%),
inhaled b-agonists/other drugs for obstructive airway
disease (10.8%) and systemic selective b2-agonists (7.0%);
these prior treatments were well balanced across the
three treatment groups.
Efficacy
At the end of the treatment period, increases in FEV1
60-min post-dose compared with baseline were signifi-
cantly greater in the formoterol 4.5 and 9 μg bid groups
(formoterol 4.5 μg: 112.6% of baseline; formoterol 9 μg:
113.4% of baseline; p < 0.001 for both groups) than in
the placebo group (Table 2; Figure 2). No difference
could be detected (0.7%) between the formoterol 4.5 μg
and 9 μg bid groups (ratio of formoterol 9 μg vs. 4.5 μg
100.7%; p = 0.643)(Figure 2).
Significantly greater (p < 0.05) improvements in all of
the secondary outcome measures (vs. baseline) were
observed with the formoterol 4.5 and 9 μgb i dg r o u p s
compared with those seen in the placebo group (Tables 2
and 3). While both formoterol 4.5 and 9 μg bid signifi-
cantly improved the SGRQ total score compared with
placebo (-3.74 and -4.45, respectively; both p ≤ 0.001),
the proportion of patients with a clinically relevant
improvement in SGRQ total score of > 4 units was sta-
tistically significantly greater for formoterol 9 μgb i dv s .
placebo (59.2% vs. 41.3%; p < 0.001) but not formoterol
4.5 μg bid vs. placebo (50.2% vs. 41.3%; p = 0.0682) (Fig-
ure 3). The difference between the two formoterol doses
in the proportion of patients with an improvement in
SGRQ total score of > 4 units approached statistical sig-
nificance (p = 0.0757). A similar profile was observed
when the SGRQ impact domain was evaluated sepa-
rately (Figure 3).
Similarly, while both formoterol 4.5 and 9 μgb i ds i g -
nificantly reduced the use of salbutamol as reliever med-
ication compared with placebo (9 μg vs. placebo
difference: -0.55, p < 0.001; 4.5 μg vs. placebo difference:
-0.27, p = 0.027), the reduction observed in patients
receiving formoterol 9 μg bid was significantly greater
than that seen in those receiving 4.5 μg bid (9 μg vs. 4.5
μg difference: -0.27, p = 0.029) (Table 3; Figure 4).
Tolerability
Formoterol was well tolerated during 12 weeks’ treat-
m e n t ;o v e r a l l ,9 9a d v e r s ee v ents were reported by 69/
206 (34%) patients receiving formoterol 4.5 μgb i d ,8 7
adverse events by 63/199 (32%) patients receiving for-
moterol 9 μg bid and 100 adverse events by 69/208
(33%) patients receiving placebo. The majority of
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Page 3 of 9Table 1 Patients’ baseline characteristics by treatment group at study entry (visit 2)
Placebo Formoterol
4.5 μg
Formoterol
9 μg
N 208 206 199
Mean age, years (range) 66.3 (40-86) 66.7 (41-85) 67.2 (44-88)
Patients ≥ 65 years, % 59.6% 64.6% 60.8%
Male, % 89.4% 88.8% 85.4%
Japanese/European, n (%) 110/98 (52.9%/47.1%) 106/100 (51.5%/48.5%) 108/91 (54.3%/45.7%)
Mean smoking pack years (range) 47.4 (10-152) 46.1 (10-150) 46.5 (11-175)
Mean duration of disease, years (range) 4.3 (0-25) 4.2 (0-39) 4.9 (0-34)
Mean FEV1, L (range)
a 1.37
(0.48-3.17)
1.30
(0.48-3.10)
1.30
(0.25-2.72)
Mean FEV1, % of predicted normal (range)
a
52.5
(16.6-83.7)
50.4
(22.0-79.4)
51.5
(9.3-79.5)
Patients with FEV1 ≤ 50%, % 43.3% 50.5% 48.2%
Mean FEV1/FVC ratio, % (range)
a 45.6
(20.5-68.8)
44.6
(23.0-70.4)
46.5
(18.1-77.2)
Mean FEV1 reversibility, % (range) 11.3
(-30.3-67.2)
10.5
(-17.9-61.6)
10.7
(-57.4-63.6)
aPre-bronchodilator value.
Patients enrolled: N=766
Patients randomized: N=613
Patients excluded: N=153
• Incorrect enrolment: N=96
• Adverse event: N=17
• Voluntary discontinuation: N=32
• Severe protocol non-compliance: N=1
• Other: N=7
Placebo
N=208
Formoterol 4.5 μg bid
N=206
Formoterol 9 μg bid
N=199
Placebo
N=186
Formoterol 4.5 μg bid
N=195
Formoterol 9 μg bid
N=182
Randomized
Completed 
Patients discontinued: N=22
• Adverse event: N=10
• Voluntary discontinuation: 
N=11
• Lost to follow-up: N=12
Patients discontinued: N=11
• Adverse event: N=6
• Voluntary discontinuation:
N=4
• Severe protocol 
non-compliance: N=1
Patients discontinued: N=17
• Adverse event: N=8
• Voluntary discontinuation: 
N=6
• Lost to follow-up: N=2
• Other: N=1
Figure 1 Patients flow through the study.
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Page 4 of 9adverse events were of mild or moderate intensity and
the three treatment groups displayed similar patterns of
a d v e r s ee v e n t s( T a b l e4 ) .T h em o s tf r e q u e n t l yr e p o r t e d
adverse events were nasopharyngitis, COPD exacerba-
tion, and bronchitis complication.
Two deaths were reported in the formoterol 4.5 μg bid
group, one as a result of acute sudden cardiopulmonary
failure and the second due to unknown causes (this was
in a 77-year-old male; cause of death was classified as
respiratory standstill); neither was considered by the
investigators to be related to study treatment. Serious
adverse events were reported by 4 patients receiving for-
moterol 4.5 μg bid, 7 patients taking formoterol 9 μg
bid and 4 patients on placebo. Six patients discontinued
treatment due to adverse events in the formoterol 4.5
μg bid group, 8 patients discontinued in the 9 μgb i d
group and 10 discontinued in the placebo group.
There were no clinically significant changes in any of
the three treatment groups in mean values over time for
Table 2 Mean values at baseline and post-treatment for
spirometric and other parameters
Placebo
(n = 208)
Formoterol
4.5 μg
(n = 206)
Formoterol
9 μg
(n = 199)
60-min post-dose FEV1,L
Baseline 1.23 1.18 1.16
Post-treatment 1.25 1.33 1.31
Ratio to baseline (%) 101.3 112.6 113.4
Pre-dose FEV1,L
Baseline 1.23 1.18 1.16
Post-treatment 1.24 1.23 1.21
Ratio to baseline (%) 99.8 104.5 104.7
5-min post-dose FEV1,L
Baseline 1.23 1.18 1.16
Post-treatment 1.24 1.30 1.28
Ratio to baseline (%) 101.3 110.2 110.2
60-min post-dose FVC, L
Baseline 2.77 2.71 2.61
Post-treatment 2.82 2.98 2.87
Ratio to baseline (%) 102.1 109.7 109.9
Pre-dose FVC, L
Baseline 2.77 2.71 2.61
Post-treatment 2.80 2.81 2.70
Ratio to baseline (%) 100.7 103.6 103.4
5-min post-dose FVC, L
Baseline 2.77 2.71 2.61
Post-treatment 2.80 2.94 2.84
Ratio to baseline (%) 101.6 108.5 108.9
Morning PEF, L/min
Run-in 223.8 211.9 215.0
Treatment 227.6 228.1 233.5
Change from run-in 3.6 16.3 18.3
Evening PEF, L/min
Run-in 233.8 221.4 221.9
Treatment 236.5 234.6 237.5
Change from run-in 2.4 13.2 15.8
Night-time awakening,
score/day
Run-in 0.73 0.66 0.83
Treatment 0.68 0.53 0.66
Change from run-in -0.05 -0.13 -0.17
Breathlessness, score/day
Run-in 1.65 1.51 1.72
Treatment 1.38 1.11 1.28
Change from run-in -0.26 -0.41 -0.45
Cough, score/day
Run-in 1.46 1.44 1.63
Treatment 1.26 1.11 1.21
Change from run-in -0.20 -0.33 -0.41
Total symptom score
Run-in 3.84 3.61 4.19
Treatment 3.32 2.75 3.14
Change from run-in -0.51 -0.86 -1.04
Table 2 Mean values at baseline and post-treatment for
spirometric and other parameters (Continued)
Use of salbutamol,
inhalations/day
Run-in 1.86 2.09 2.40
Treatment 1.63 1.52 1.50
Change from run-in -0.23 -0.60 -0.97
SGRQ total score
Baseline 44.9 43.4 44.0
Last available score 42.9 38.2 38.2
Change from baseline -2.0 -5.5 -6.4
* *
ϵϬ
ϭϬϬ
ϭϭϬ
ϭϮϬ
WůĂĐĞďŽ ϰ͘ϱƵŐ ϵƵŐ
ZĂƚŝŽƚŽďĂƐĞůŝŶĞ;йͿ
Ύ Ύ
Figure 2 FEV1 at 60-min post-dose in patients with COPD
receiving formoterol or placebo; *p < 0.001 vs. placebo. FEV1 at
60-min post-dose (ratio to baseline) in patients with COPD receiving
formoterol 4.5 or 9 μg twice daily or placebo. *p < 0.001 vs.
placebo.
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Page 5 of 9ECG, pulse rate, blood pressure and any of the haema-
tological, clinical chemistry and urinalysis variables.
Discussion
The results of the current study demonstrate that for-
moterol at doses of 4.5 μga n d9μg bid is significantly
more effective in improving lung function (FEV1 60-min
post-dose) in Japanese and European patients with
COPD compared with placebo. The results of the
secondary variables, both those related to lung function
(for example, morning and evening PEF) and those
related to daily diary card data (for example, COPD
symptom score, and reliever medication use) and
health-related quality-of-life (SGRQ total score) support
the findings observed with the primary study endpoint.
It is noteworthy that a clinically relevant benefit for for-
moterol 9 μg bid compared with 4.5 μg bid was demon-
strated for the secondary endpoint of improved SGRQ
Table 3 Differences between treatments (ratio for FEV1 and FVC, absolute values for other variables) for spirometric
and other parameters
Variable 9 μg vs. Placebo (p-value) 4.5 μg vs. Placebo (p-value) 9 μg vs. 4.5 μg
(p-value)
60-min post-dose FEV1, L 1.11 (< 0.001) 1.11 (< 0.001) 1.01 (0.643)
Pre-dose FEV1, L 1.04 (0.002) 1.04 (0.002) 1.00 (0.955)
5-min post-dose FEV1, L 1.09 (< 0.001) 1.09 (< 0.001) 1.00 (0.984)
60-min post-dose FVC, L 1.07 (< 0.001) 1.07 (< 0.001) 0.99 (0.642)
Pre-dose FVC, L 1.02 (0.135) 1.03 (0.026) 0.99 (0.483)
5-min post-dose FVC, L 1.07 (< 0.001) 1.07 (< 0.001) 1.00 (0.982)
Morning PEF, L/min 15.30 (< 0.001) 12.86 (< 0.001) 2.45 (0.360)
Evening PEF, L/min 13.78 (< 0.001) 10.85 (< 0.001) 2.93 (0.260)
Night-time awakening, score/day -0.09 (0.038) -0.10 (0.020) 0.01 (0.816)
Breathlessness, score/day -0.17 (0.002) -0.18 (0.001) 0.01 (0.822)
Cough, score/day -0.13 (0.013) -0.12 (0.023) -0.01 (0.809)
Total symptom score -0.41 (0.001) -0.62 (0.001) -0.25 (0.883)
Use of salbutamol, inhalations/day -0.55 (< 0.001) -0.27 (0.027) -0.27 (0.029)
SGRQ total score -4.45 (0.001) -3.74 (0.001) -0.71 (0.553)
Ϭ
ϭϬ
ϮϬ
ϯϬ
ϰϬ
ϱϬ
ϲϬ
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
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Ŷ
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0
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0
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0
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n
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Figure 3 Percentage of patients with a SGRQ improvement rate > 4; *p < 0.001 vs. placebo.
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for formoterol 9 μgb i dv s .4 . 5μg bid for use of relie-
ver medication. The use of reliever medication was sig-
nificantly lower in the formoterol 9 μgb i dg r o u p
compared with 4.5 μg bid, and the proportion of
patients with a clinically relevant improvement in
SGRQ total score of > 4 units [13] was statistically
significantly greater for formoterol 9 μg bid vs. placebo
but not formoterol 4.5 μg bid vs. placebo. While these
results might not be that surprising, the additional
reduction in reliever medication use and increase in
the proportion of patients with a clinically relevant
Figure 4 Mean change from baseline in use of salbutamol over time.
Table 4 Adverse events with an incidence > 1
Adverse event, n (%) Placebo
(n = 208)
Formoterol 4.5 μg bid (n = 206) Formoterol 9 μg bid (n = 199)
Nasopharyngitis 20 (9.6) 24 (11.7) 25 (12.6)
COPD exacerbation 17 (8.2) 10 (4.9) 8 (4.0)
Bronchitis complication 2 (1.0) 1 (0.5) 7 (3.5)
Pneumonia 0 2 (1.0) 3 (1.5)
Ill-defined disorder 2 (1.0) 2 (1.0) 1 (0.5)
Back pain 3 (1.4) 0 1 (0.5)
Dizziness 1 (0.5) 2 (1.0) 1 (0.5)
Glucose present in urine 2 (1.0) 2 (1.0) 0
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is some additional benefit of formoterol 9 μgb i do v e r
4.5 μg bid in this COPD patient population.
Both formoterol 4.5 and 9 μg bid for 12 weeks were
well tolerated in Japanese and European patients with
COPD. No clinically important safety differences
between the formoterol 4.5 and 9 μgb i dd o s e sw e r e
observed. Concerns were raised regarding the ongoing
safety of LABA therapy in patients with COPD following
the publication of a meta-analysis of 22 studies of at
least 3-month duration that suggested an increased risk
of death with LABA therapy compared with placebo
[10]. However, this analysis has been countered by a
more recent meta-analysis which applied more rigorous
study selection criteria and excluded studies with dupli-
cate data; it also included studies of at least 1-month
duration [11]. This latter meta-analysis found that
LABAs reduced severe exacerbations compared with
placebo (relative risk 0.78; 95% CI: 0.67-2.64) and that
there was no significant difference between LABA and
placebo with regard to the risk of respiratory death
(relative risk 1.09; 95% CI: 0.45-2.64) [11]. The results of
the current 12-week study are consistent with the latter
meta-analysis; two deaths did occur in the study and
although both patients had been randomized to formo-
terol 4.5 μg bid, neither death was considered to be
related to study treatment.
Bronchodilator therapy represents the mainstay of
treatment for patients with COPD. The place of LABA
therapy as a bronchodilator for COPD has been revis-
ited in recent years. LABA monotherapy is more com-
monly used in the management of COPD than it is in
the management of asthma where LABA therapy is
combined with concomitant ICS and is regarded with
caution following the results of the Salmeterol Multi-
center Asthma Research Trial [14], which demon-
strated an increased risk of death in the salmeterol
treatment arm. These data led to a black box warning
being applied to both salmeterol and formoterol by
the US Food and Drug Administration. Clinical studies
have confirmed the efficacy of formoterol for broncho-
dilation in COPD in terms of improved lung function,
symptoms, exacerbations, and HRQL [15-20]. Further-
more, formoterol has been shown to exert a faster
onset of bronchodilatory effect compared with salme-
terol in patients with COPD [21]. These data, com-
bined with the results of the current study and the
encouraging efficacy meta-analysis data described ear-
lier [11], support the role of formoterol bronchodilator
therapy in patients with COPD, with the potential
caveat of excluding patients with an asthma compo-
nent, as recommended in the current GOLD guide-
lines [9].
Conclusion
The results of the current study confirm that formoterol
at doses of 4.5 and 9 μg bid is an effective and well tol-
erated first-line treatment option in the management of
COPD, with additional benefits evident at the higher
dose in terms of a reduced need for reliever medication
and improved health-related quality-of-life.
List of abbreviations
ANCOVA: analysis of covariance; bid: twice daily; CI: confidence interval;
COPD: chronic obstructive pulmonary disease; ECG: electrocardiogram; FEV1:
forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD:
Global Initiative for Chronic Obstructive Lung Disease; HRQL: health-related
quality-of-life; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LOCF:
last-observation-carried-forward; PEF: peak expiratory flow; pMDI: pressurized
metered-dose inhaler; SGRQ: St George’s Respiratory Questionnaire.
Acknowledgements and funding
The study was funded by AstraZeneca.
Editorial services were provided by Ian Wright, Wright Medical
Communications Ltd, Hartford, UK, and funded by AstraZeneca.
Author details
1Clinica Medic Or, Calea Vitan no 106, Postcode 031298, Bucharest, Romania.
2Kurume University, 67 Asahi-cho, Kurume-shi, Fukuoka 830-0011, Japan.
3Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Tokyo,
Japan.
4Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto-shi, Kyoto 606-
8501, Japan.
5Hokkaido University, Nishi 7-chome, Kita 15-jo, Kita-ku,
Sapporo-shi, Hokkaido 060-8638, Japan.
6Wakayama Medical University, 811-1
Kimiidera, Wakayama-shi, Wakayama 641-8509, Japan.
Authors’ contributions
MB and MI made significant contributions to the conception and design of
the study. MB, HA, YF, MM, MN and MI made significant contributions to the
acquisition of data, analysis and interpretation of data, and drafting of the
manuscript. All authors read and approved the final manuscript.
Competing interests
Professor Miron Bogdan has received honoraria over the past year from
Glaxo SmithKline, AstraZeneca, Pfizer and Actelion. These have not
inappropriately influenced his work. Professor Bogdan has never received
financial support from the tobacco industry. Professor Hisamichi Aizawa has
served as a member of scientific advisory boards, received honoraria for
lectures or research grants from GlaxoSmithKline KK, Nippon Boehringer
Ingelheim, Novartis Pharma KK and AstraZeneca KK. Professor Yoshinosuke
Fukuchi has received honoraria for lectures from GlaxoSmithKline KK, Nippon
Boehringer Ingelheim, Novartis Pharma KK, Abbott Japan, Otsuka
Pharmaceutical, and AstraZeneca KK. Professor Michiaki Mishima has served
as a member of scientific advisory boards, received honoraria for lectures or
research grants from GlaxoSmithKline KK, Nippon Boehringer Ingelheim,
Pfizer Japan, MSD KK, Kyorin Pharmaceutical and AstraZeneca KK. Professor
Masaharu Nishimura has served as a member of scientific advisory boards,
received honoraria for lectures or research grants from GlaxoSmithKline KK,
Nippon Boehringer Ingelheim, Novartis Pharma KK, Abbott Japan, Pfizer
Japan, MSD KK, Kyorin Pharmaceutical and AstraZeneca KK. Professor
Masakazu Ichinose has served as a member of scientific advisory boards,
received honoraria for lectures or research grants from GlaxoSmithKline KK,
Nippon Boehringer Ingelheim, Novartis Pharma KK, Abbott Japan and
AstraZeneca KK.
The study was funded by AstraZeneca.
Received: 17 February 2011 Accepted: 15 November 2011
Published: 15 November 2011
References
1. Chamberlain AM, Schabath MB, Folson AR: Associations of chronic
obstructive pulmonary disease with all-cause mortality in Blacks and
Bogdan et al. BMC Pulmonary Medicine 2011, 11:51
http://www.biomedcentral.com/1471-2466/11/51
Page 8 of 9Whites: the atherosclerosis risk in communities (ARIC) study. Ethn Dis
2009, 19:308-314.
2. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Löfdahl CG:
Mortality in GOLD stages of COPD and its dependence on symptoms of
chronic bronchitis. Respir Res 2005, 6:98.
3. Lung Health Study Research Group: Effect of inhaled triamcinolone on
the decline in pulmonary function in chronic obstructive pulmonary
disease. N Engl J Med 2000, 343:1902-1999.
4. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB,
Ohlsson SV: Long-term treatment with inhaled budesonide in persons
with mild chronic obstructive pulmonary disease who continue
smoking. N Engl J Med 1999, 340:1948-1953.
5. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H:
Maintenance therapy with budesonide and formoterol in chronic
obstructive pulmonary disease. Eur Respir J 2003, 22:912-919, Erratum in:
Eur Respir J 2004, 24:1075.
6. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J,
Maden C, TRial of Inhaled STeroids ANd long-acting beta2 agonists study
group: Combined salmeterol and fluticasone in the treatment of chronic
obstructive pulmonary disease:a randomised controlled trial. Lancet 2003,
361:449-456, Erratum in: Lancet 2003, 361:1660.
7. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S,
Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the
management of chronic obstructive pulmonary disease. Eur Respir J 2003,
21:74-81, Erratum in: Eur Respir J 2003, 21:912.
8. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW,
Yates JC, Vestbo J, TORCH investigators: Salmeterol and fluticasone
propionate and survival in chronic obstructive pulmonary disease. N
Engl J Med 2007, 356:775-789.
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global
strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease (updated 2010).[http://www.goldcopd.org/
].
10. Salpeter SR, Buckley NS, Salpeter EE: Meta-analysis: anticholinergics, but
not β-agonists, reduce severe exacerbations and respiratory mortality.
Int J COPD 2006, 21:1011-1019.
11. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R: Safety of long-acting β-
agonists in stable COPD: a systematic review. Chest 2008, 133:1079-1087.
12. Campbell M, Eliraz A, Johansson G, Tornling G, Nihlén U, Bengtsson T,
Rabe K: Formoterol for maintenance and as-needed treatment of chronic
obstructive pulmonary disease. Respir Med 2005, 99:1511-1520.
13. Jones PW: Interpreting thresholds for a clinically significant change in
health status in asthma and COPD. Eur Respir J 2002, 19:398-404.
14. Nelson HS, Weiss ST, Bleecker ET, Yancey SW, Dorinsky PM: The Salmeterol
Multicenter Asthma Research Trial. Chest 2006, 129:15-26.
15. Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gros V, Kottakis J, Bourdeix I:
Rapid onset of bronchodilation in COPD: a placebo-controlled study
comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
Respir Med 2001, 95:817-821.
16. Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, Siafakas N:
Effects of formoterol and salmeterol on resting inspiratory capacity in
COPD patients with poor FEV(1) reversibility. Curr Med Res Opin 2004,
20:581-586.
17. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D,
Della Cioppa G, Formoterol in Chronic Obstructive Pulmonary Disease I
Study Group: Inhaled formoterol dry powder versus ipratropium bromide
in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001,
164:778-784.
18. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S: Effect of
formoterol, tiotropium, and their combination in patients with acute
exacerbation on chronic obstructive pulmonary disease: a pilot study.
Respir Med 2006, 100:1925-1932.
19. Maesen BL, Westermann CJ, Duurkens VA, van den Bosch JM: Effects of
formoterol in apparently poorly reversible chronic obstructive
pulmonary disease. Eur Respir J 1999, 13:1103-1108.
20. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della
Cioppa G, Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II
Study Group: Comparison of the efficacy, tolerability, and safety of
formoterol dry powder and oral, slow-release theophylline in the
treatment of COPD. Chest 2002, 121:1058-1069.
21. Kottakis J, Cioppa GD, Creemers J, Greefhorst L, Lecler V, Pistelli R,
Overend T, Till D, Rapatz G, Le Gros V, Bouros D, Siafakas N: Faster onset of
bronchodilation with formoterol than with salmeterol in patients with
stable, moderate to severe COPD: results of a randomized, double-blind
clinical study. Can Respir J 2002, 9:107-115.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2466/11/51/prepub
doi:10.1186/1471-2466-11-51
Cite this article as: Bogdan et al.: Efficacy and safety of inhaled
formoterol 4.5 and 9 μg twice daily in Japanese and European COPD
patients: Phase III study results. BMC Pulmonary Medicine 2011 11:51.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bogdan et al. BMC Pulmonary Medicine 2011, 11:51
http://www.biomedcentral.com/1471-2466/11/51
Page 9 of 9